Next Article in Journal
Piceatannol, a Natural Analog of Resveratrol, Exerts Anti-angiogenic Efficiencies by Blockage of Vascular Endothelial Growth Factor Binding to Its Receptor
Next Article in Special Issue
Synthesis and Physicochemical Properties of 2,7-Disubstituted Phenanthro[2,1-b:7,8-b’]dithiophenes
Previous Article in Journal
Selective Intramolecular Dehydrocyclization of Co-Porphyrin on Au(111)
Previous Article in Special Issue
Structural and Photophysical Properties of 2,1,3-Benzothiadiazole-Based Phosph(III)azane and Its Complexes
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 25
Issue 17
10.3390/molecules25173768
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Synthesis of 2-((2-(Benzo[d]oxazol-2-yl)-2H-imidazol-4-yl)amino)-phenols from 2-((5H-1,2,3-Dithiazol-5-ylidene)amino)phenols through Unprecedented Formation of Imidazole Ring from Two Methanimino Groups

by
Ilia V. Baranovsky
1,
Lidia S. Konstantinova
1,2,
Mikhail A. Tolmachev
1,
Vadim V. Popov
2,
Konstantin A. Lyssenko
3,4 and
Oleg A. Rakitin
1,2,*
1
N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, 119991 Moscow, Russia
2
Nanotechnology Education and Research Center, South Ural State University, 454080 Chelyabinsk, Russia
3
Department of Chemistry, M. V. Lomonosov Moscow State University, Leninskiye Gory, 1, 119991 Moscow, Russia
4
G. V. Plekhanov Russian University of Economics, 36 Stremyanny Per., 117997 Moscow, Russia
*
Author to whom correspondence should be addressed.
Molecules 2020, 25(17), 3768; https://doi.org/10.3390/molecules25173768
Submission received: 28 July 2020 / Revised: 14 August 2020 / Accepted: 18 August 2020 / Published: 19 August 2020
(This article belongs to the Special Issue Polysulfur- and Sulfur-Nitrogen Heterocycles)
Browse Figures
Versions Notes

Abstract

A new synthetic pathway to four substituted imidazoles from readily available 2-((4-aryl(thienyl)-5H-1,2,3-dithiazol-5-ylidene)amino)phenols has been developed. Benzo[d]oxazol-2-yl(aryl(thienyl))methanimines were proved as key intermediates in their synthesis. The formation of an imidazole ring from two methanimine derivatives likely includes the opening of one benzoxazole ring followed by ring closure by intermolecular nucleophilic attack of the N-methanimine atom to a carbon atom of another methanimine.

Graphical Abstract

1. Introduction

1,2,3-Dithiazoles are one of the most investigated groups of five membered sulfur–nitrogen heterocycles [1,2,3]. In addition to the utility of these heterocyclic compounds as potent biologically active compounds [4,5,6,7,8], they are efficient precursors for functional materials applied in electronics and spintronics [9,10,11,12,13,14]. The chemistry of monocyclic 1,2,3-dithiazoles has attracted considerable attention through recent decades [1,2,3] due to the easy availability of 4,5-dichloro-1,2,3-dithiazolium chloride (Appel’s salt, 1) [15,16]. 4-Chlorosubtituted monocyclic 1,2,3-dithiazoles [1,2,3,17,18,19,20] were thoroughly investigated. The most interesting and valuable parts of this reactivity are various rearrangements of 4-chloro-1,2,3-dithiazoles, especially 5-arylimino derivatives (i.e., 2), which showed a great potential for the synthesis of multiple heterocycles, such as 1,2,4-thiadiazoles [21], isothiazoles [22], benzoxazines and benzothiazines [23], benzimidazoles [24], quinazolones [25], benzothiazoles [26] and benzoxazoles (3, see Scheme 1) [26,27,28], and many others [1,2,29,30]. The formation of these heterocycles was the result of the presence of a chlorine atom at the C-4 position of the 1,2,3-dithiazole ring, which can be readily removed as a chloride anion. Presumably, one might expect that the exchange of 4-chlorine atom in 1,2,3-dithiazoles to poorly leaving groups, such as aryl or hetaryl, can significantly change reaction results. There is only one example of the benzoxazole ring formation (5) from 2-((4-(4-nitrophenyl)-5H-1,2,3-dithiazol-5-ylidene)amino)phenol 4 [28]. 4-Substituted 1,2,3-dithiazoles, except 4-chloro-1,2,3-dithiazoles, are much less available, and their chemistry still needs further developments. A couple of years ago, an easy one pot protocol for the preparation of the 4-substituted 1,2,3-dithiazolium chlorides from readily available acetoximes, disulfur dichloride and pyridine in MeCN has been developed [31]. The treatment of these salts was prepared in situ with aniline afforded 5-phenylimino-1,2,3-dithiazoles in low to moderate yields. Other 5-arylimino-1,2,3-dithiazoles including o-substituted derivatives, which can be used for the synthesis of new heterocyclic systems, were not obtained.
Herein, we report the synthesis of 2-((4-aryl(hetaryl)-5H-1,2,3-dithiazol-5-ylidene)amino)phenols, their thermal ring transformation into benzo[d]oxazol-2-yl(aryl(hetaryl)methanimines, followed by their unprecedented dimerization of into imidazole derivatives.

2. Results and Discussion

The treatment of 4-aryl(thienyl)-5-chloro-1,2,3-dithiazolium chlorides 6, obtained in situ from acetoximes, disulfur dichloride, and pyridine in MeCN in a conditions described by us earlier [31], with o-aminophenol and pyridine at 0 °C and further stirring at room temperature for 2 h, gave imines 6 in moderate to low yields (Scheme 2). All our attempts to increase the yield of imines 7 by varying the base (DABCO, N-ethyldiisopropylamine or o-aminophenol), temperature of the reaction from −20 °C to room temperature, and time of dithiazolium salt 6 formation, resulted in a decrease in the yield of the target product to trace amounts. The low yields of imines 7 can be explained by low stability of the dithiazolium salts 6 at room temperature.
The thermal behavior of imines 7 was investigated in various solvents (chloroform, benzene, toluene, methanol, ethanol, acetonitrile). The imines 7 were found to be inert by prolonged refluxing (8 h) in chloroform (bp 61 °C) and benzene (bp 80 °C) and were isolated from the reaction mixtures in practically quantitative yields. The heating of the compounds in more polar solvent—ethanol (95% or anhydrous) afforded (benzo[d]oxazol-2-yl)arylmethanones 8 in high yields (Scheme 3).
When continuing the study of thermolysis of imines 7, it was found that when heated in methanol (bp 65 °C), the formation of compounds other than methanones 8 is observed. The structure of the methanimines 9 has been confirmed by NMR and IR spectroscopy and mass-spectrometry and was unambiguously determined by an X-ray diffraction study of thienylmethanimine 9f (Figure 1). Presumably, the formation of imines 9 and aroylbenzoxazoles 8 can be explained by the collapse of phenolic oxygen onto C-5 of the dithiazole ring with loss of HCl and sulfur followed by hydrolysis of methanimines 9 [28]. The difference in the result of reactions in methanol and ethanol can be explained by the higher stability of imine 8 in methanol; for example, NMR spectra of imines 8 were successfully obtained in deuteromethanol, while our attempts to obtain similar spectra in deuteroethanol failed due to their decomposition (hydrolysis).
In the crystal, 9f exists in the form of an isomer with the imine group in transposition to the C=N bond of the benzo[d]oxazole ring. Such conformation can be stabilized by the intramolecular N4-H···O1 and/or C14-H···N3 interactions. In order to estimate the stability of two possible isomers, we performed PBE1PBE/def-2-TZVP calculations with the empirical dispersion corrections. The optimization at the above level was followed by the evaluation of the harmonic vibration frequencies. Full geometry optimization revealed that both isomers were characterized by almost equal energy with a small stabilization (0.87 kcal/mol) of the experimentally observed isomer (Figure 2).
The topological analysis of the electron density distribution function ρ(r) within Bader’s quantum theory of “Atoms in Molecule’’ (QTAIM) [32] revealed that in both isomers, the imine group did not participate in the formation of N-H···N or N-H···O interactions. In contrast, for C-H···O or C-H···N contacts, the critical points (3, −1) were located, and thus we can conclude that both of them are attractive interactions. The energy of the above intramolecular C-H···N and C-H···O interactions according to the correlation suggested by Espinosa et al. [33] was 3.1 and 2.9 kcal/mol.
Despite conjugation in the 9f, the crystal molecule was not planar with the dihedral angle between the thiophen ring and rest molecule equal to 5.6°. Such conformation in 9f is clearly the consequence of crystal packing. It was found out that the C=N-H group did not participate in any intermolecular hydrogen bond and that molecules were assembled by stacking interactions into infinite columns with the shortest C5···C10 contact equal to 3.405(2)Å.
Further investigation of imines 7 thermolysis in toluene, acetonitrile, or THF showed the formation of new compounds 10 (TLC data) along with methanones 8 and methanimines 9. This was confirmed by a prolonged (4–38 h) refluxing of methanimines 9 in MeCN, which led to the formation of products 10, selectively, with good yields. Mass spectrometry, HRMS, and 1H and 13C NMR data showed that they are products of dimerization of methanimines 9 (Scheme 4).
According to the literature search in SciFinder and Reaxys databases, no similar dimerization reaction of imino derivatives was published in the literature. The structure of imidazoles 10 was finally proved by the X-ray analysis for 4-fluorophenyl analogue 10b (Figure 3).
The interesting feature of 10b was the presence of the shortened N4-H···H-C18 intramolecular contact with H···H distance (with the account of C-H and N-H bond normalization) equal to 2.08Å. It is reasonable to propose that this shortened contact is clearly the consequence of the competition of the destabilization due to steric hindrance between atoms of amino-phenol and of fluorophenyl and stabilization due to conjugation of this substituents with the central 2H-imidazol ring. In order to analyze the nature of the observed NH···HC contact in the experimental conformation, we performed the optimization of hydrogen atom positions with all other parameters fixed. The consequent topological analysis of ρ(r) revealed that this shortened intramolecular contact corresponded to attractive interaction (Figure 4). Furthermore, the full optimization practically did not change the torsion angles, and the above H···H contact became as short as 2.068Å with CHH and NH···H angles equal to 116.2 and 96.1°. Thus, we can conclude that the observed conformation was not the consequence of the crystal packing effect but rather the inherent feature of this molecule.
Crystal molecules were assembled into a centrosymmetric dimer due to the formation of the O2-H···N3 (O···N 2.840(2)Å) hydrogen bonds. The latter dimer was additionally stabilized by the stacking interactions with the interplane distance of ~3.4 Å (Figure 5).

Mechanistic Rationale

The described procedure provides a new synthetic pathway to imidazole derivatives from compounds 9 containing methanimine and benzoxazole fragments. To the best of our knowledge, this reaction has not been described so far. We assume that the first step is the nucleophilic attack of the N-methanimine atom into the carbon atom of the oxazole ring with the opening of the benzoxazole ring to o-aminophenol moiety, which is well described for many benzoxazoles [34,35,36]. The result of this reaction is the formation of compounds containing three consecutive methanimino groups 11. According to the search from Reaxys database, such structures were not known. The second intramolecular nucleophilic attack of the methanimino-nitrogen to the carbon atom of another methanimino group led to the 2-aminoimidazole ring closure (Scheme 5).

3. Experimental Section

3.1. General Methods and Materials

The reagents were purchased from commercial sources and used as received. Ethan-1-one oximes were prepared according to the published methods [37] and characterized by NMR spectra. All synthetic operations were performed under a dry argon atmosphere. Solvents were purified by distillation from the appropriate drying agents. Elemental analyses were performed on a 2400 Elemental Analyzer (Perkin Elmer Inc., Waltham, MA, USA). Melting points were determined on a Kofler hot-stage apparatus and were uncorrected. 1H and 13C NMR spectra were taken with a Bruker AM-300, AVANCE DRX 500, and AVANCE II 600 machines (Bruker Ltd., Moscow, Russia) with TMS as the standard. J values are given in Hz. MS spectra (EI, 70 eV) were obtained with a Finnigan MAT INCOS 50 instrument (Thermo Finnigan LLC, San Jose, CA, USA). High-resolution MS spectra were measured on a Bruker micrOTOF II instrument using electrospray ionization (ESI). The measurement was operated in a positive ion mode (interface capillary voltage −4500 V) or in a negative ion mode (3200 V); the mass range was from m/z 50 to m/z 3000 Da; external or internal calibration was performed with Electrospray Calibrant Solution (Fluka Chemicals Ltd., Gillingham, UK). A syringe injection was used for solutions in acetonitrile, methanol, or water (flow rate 3 μL·min−1). Nitrogen was applied as a dry gas; the interface temperature was set at 180 °C. IR spectra were measured with a Bruker “Alpha-T” instrument (Bruker, Billerica, MA, USA) in KBr pellets.
X-ray diffraction data for all studied compounds were collected using a SMART APEX II area-detector diffractometer (graphite monochromator, ω-scan technique) at the temperature of 120(2) K, using MoKα radiation (0.71073 Å). The intensity data were integrated by the SAINT program and corrected for absorption and decay by the multiscan method (semi-empirical from equivalents) implemented in SADABS. All structures were solved by direct methods using SHELXS [38] and were refined against F2 using SHELXL-2017 [39]. All nonhydrogen atoms were refined with anisotropic displacement parameters. All C-H hydrogen atoms were placed in ideal calculated positions and refined as riding atoms with relative isotropic displacement parameters taken as Uiso(H) = 1.2Ueq(C). The hydrogen atoms of NH and OH groups were located from the Fourier density synthesis. Detailed crystallographic information is provided in Table 1 and as Supplementary Materials in CIF format that can be obtained free of charge via http://www.ccdc.cam.ac.uk/conts/retrieving.html or from the Cambridge Crystallographic Data Centre, 12, Union Road, Cambridge CB2 1EZ, UK; fax: 44-1223-336033 using the reference CCDC numbers (Table 1).
All quantum chemistry computations were performed in the Gaussian09 program [40] using the density functional theory (PBE0) [41] and the def-2-TZVP basis set. The choice of the PBE0 functional was based on the recent paper in which errors of various DFT functionals in the reproduction of an exact electron density and energy are discussed [42]. The geometry was optimized using the very tight optimization criteria and empirical dispersion corrections on the total energy [43] with the Becke-Johnson damping (D3) [44].
Topological analyses of the ρ(r) function were performed using the AIMAll program (AIMAll (Version 16.08.17), T. Keith, TK Gristmill Software, Overland Park KS, USA, 2016 (aim.tkgristmill.com)). All expected critical points were found, and the whole set of critical points in each system satisfies the Poincaré-Hopf rule.

3.2. General Procedure for the Synthesis of 2-((4-aryl-5H-1,2,3-dithiazol-5-ylidene)amino)phenols (7)

Pyridine (0.24 mL, 3 mmol) was added dropwise at 0 to −5 °C to a stirred solution of ethanoneoxime 4 (1 mmol) and disulfur dichloride (0.16 mL, 2 mmol) in acetonitrile (10 mL) under inert atmosphere of argon. The mixture was stirred at 0 °C for 15–40 min. Then o-aminophenol (109 mg, 1 mmol) was added, the mixture was stirred at 0 °C for 30 min and followed by pyridine (0.16 mL, 2 mmol). The reaction mixture was stirred at room temperature for 2 h, filtered, and solvents were evaporated. The residue was separated by column chromatography (Silica gel Merck 60, light petroleum and then light petroleum–CH2Cl2 mixtures).
2-((4-Phenyl-5H-1,2,3-dithiazol-5-ylidene)amino)phenol (7a)
Yield 172 mg (30%). Yellow solid, m.p. 89–90 °C. Anal. calcd. for C14H10N2OS2: C, 58.72; H, 3.52; N, 9.78 found: C, 58.65; H, 3.56; N, 9.80. 1H NMR (300 MHz, CD2Cl2) δ: 8.27(s, 1H, Ar), 8.21 (d, 1H, J = 8.1, Ar), 7.74 (m, 3H, Ar), 7.57 (t, 1H, J = 7.3, Ar), 7.30 (d, 2H, J = 11.0, Ar), 7.15 (m, 1H, Ar), 7.03 (s, 1H, OH). 13C NMR (75 MHz, CD2Cl2) δ: 162.6, 161.9, 151.9, 134.7, 133.5, 130.7, 129.4, 129.1, 128.7, 120.1, 116.7, 114.8. IR, ν, cm−1: 3321, 3055, 1563, 1478, 1248, 1145, 1032, 722, 622. m/z (%): 286 (M+, 31), 222 (47), 119 (100), 91 (45). HRMS m/z (ESI) 287.0312 (calcd. for C14H10N2OS2 [M + H]+ 287.0312).
2-((4-(4-Fluorophenyl)-5H-1,2,3-dithiazol-5-ylidene)amino)phenol (7b)
Yield 201 mg (33%). Yellow solid, m.p. 124–125 °C. Anal. calcd. for C14H9FN2OS2: C, 55.25; H, 2.98; N, 9.20 found: C, 55.20; H, 3.01; N, 9.24. 1H NMR (300 MHz, CD2Cl2) δ: 8.07 (m, 2H, Ar), 7.63 (d, 1H, J = 7.8, Ar), 7.25 (m, 3H, Ar), 7.06 (m, 2H, Ar), 6.53 (s, 1H, OH). 13C NMR (75 MHz, CD2Cl2) δ: 164.0 (J = 286), 161.4, 151.7, 134.9, 131.6, 131.5, 129.2, 120.2, 116.7, 116.0, 115.7, 115.0. IR, ν, cm−1: 3310, 1478, 1289, 1227, 1154, 1154, 862, 721. m/z (%): 304 (M+, 29), 240 (38), 183 (14), 119 (100), 91 (56). HRMS m/z (ESI) 305.0220 (calcd. for C14H10FN2OS2 [M + H]+ 305.0213).
2-((4-(4-Methoxyphenyl)-5H-1,2,3-dithiazol-5-ylidene)amino)phenol (7c)
Yield 190 mg (30%). Yellow solid, m.p. 137–138 °C. Anal. calcd. for C15H12N2O2S2: C, 56.94; H, 3.82; N, 8.85 found: C, 57.04; H, 3.78; N, 8.85.). 1H NMR (300 MHz, CD2Cl2) δ: 8.03 (d, 2H, J = 8.8, Ar), 7.64 (d, 1H, J = 7.7, Ar), 7.26 (t, 1H, J = 7.3, Ar), 7.06 (m, 4H, Ar), 6.63 (s, 1H, OH), 3.91 (s, 3H, CH3). 13C NMR (75 MHz, CD2Cl2) δ: 162.4, 161.9, 161.7, 151.7, 135.0, 130.9, 129.4, 128.9, 120.1, 116.7, 114.8, 114.1, 55.7. IR (KBr), ν, cm−1: 3376, 2836, 1609, 1479, 1313, 1250, 1172, 1032, 801, 727, 612. m/z (%): 316 (M+, 15), 252 (53), 183 (9), 133 (100), 119 (47), 91 (34). HRMS m/z (ESI)317.0417 (calcd. for C15H13N2O2S2 [M + H]+ 317.0413).
2-((4-(4-Bromophenyl)-5H-1,2,3-dithiazol-5-ylidene)amino)phenol (7d)
Yield 80 mg (11%). Yellow solid, m.p. 152–153 °C. Anal. calcd. for C14H9BrN2OS2: C, 46.03; H, 2.48; N, 7.67 found: C, 45.95; H, 2.53; N, 7.71. 1H NMR (300 MHz, CD2Cl2) δ: 7.95 (d, 2H, J = 8.1, Ar), 7.68 (d, 2H, J = 8.1, Ar), 7.61 (d, 1H, J = 8.1, Ar), 7.26 (t, 1H, J = 7.7, Ar), 7.06 (m, 2H), 6.54 (s, 1H, OH). 13C NMR (75 MHz, CD2Cl2) δ: 161.9, 161.2, 151.6, 134.9, 132.3, 131.9, 130.9, 129.1, 125.1, 120.1, 116.7, 115.0. IR, ν, cm−1: 3411, 3057, 1583, 1477, 1253, 1229, 1153, 1068, 1010, 851, 805, 772, 740, 725, 678. m/z (%): 366 (M+ +2, 11), 364 (M+, 9) 300 (12), 183 (27), 150 (5), 119 (100), 91 (47). HRMS m/z (ESI)366.9384 (calcd. for C14H10BrN2OS2 [M + H]+ 366.9384).
2-((4-(4-Nitrophenyl)-5H-1,2,3-dithiazol-5-ylidene)amino)phenol (7e)
Yield 172 mg (26%). Orange solid, m.p. 140–141 °C. Anal. calcd. for C14H9N3O3S2: C, 50.74; H, 2.74; N, 12.68 found: C, 50.68; H, 2.76; N, 12.72. 1H NMR (300 MHz, CD2Cl2) δ: 8.37 (d, 2H, J = 8.9, Ar), 8.26 (d, 2H, J = 8.9, Ar), 7.61 (d, 1H, J = 8.0, Ar), 7.28 (t, 1H, J = 7.8, Ar), 7.11–7.03 (m, 2H, Ar), 6.40 (s, 1H, Ar). 13C NMR (75 MHz, CD2Cl2) δ: 161.8, 160.3, 151.5, 149.0, 139.1, 134.8, 130.5, 129.4, 123.9, 120.3, 116.6, 115.1. IR, ν, cm−1: 3395, 1560, 1480, 1218, 1152, 1042, 843, 756, 715, 696. m/z (%): 331 (M+, 41), 231 (25), 183 (15), 148 (100), 123 (14), 79 (9). HRMS m/z (ESI)332.0158 (calcd. for C14H10N3O3S2 [M + H]+ 332.0162).
2-((4-(Thiophen-2-yl)-5H-1,2,3-dithiazol-5-ylidene)amino)phenol (7f)
Yield 111 mg (19%). Orange solid, m.p. 77–78 °C. Anal. calcd. for C12H8N2OS3: C, 49.29; H, 2.76; N, 9.58 found: C, 49.21; H, 2.80; N, 9.56. 1H NMR (300 MHz, CD2Cl2) δ: 8.17 (d, 1H, J = 5.1, Ar), 7.60 (m, 2H, Ar), 7.25 (m, 2H, Ar), 7.09 (m, 2H, Ar), 6.87 (s, 1H, OH). 13C NMR (75 MHz, CD2Cl2) δ: 161.5, 156.3, 152.3, 135.3, 134.4, 131.6, 130.2, 129.4, 127.9, 120.5, 116.9, 115.6. IR, ν, cm−1: 3439, 3119, 1556, 1479, 1222, 1151, 1035, 834, 775, 711, 680. m/z (%): 292 (M+, 32), 228 (46), 195 (16), 150 (7), 119 (100), 109 (58), 91 (47). HRMS m/z (ESI)292.9869 (calcd. for C12H9N2OS3 [M + H]+ 292.9872).
2-((4-(Benzofuran-2-yl)-5H-1,2,3-dithiazol-5-ylidene)amino)phenol (7g)
Yield 63 mg (13%). Orange solid, m.p. 167–169 °C. Anal. calcd. for C16H10N2O2S2: C, 58.88; H, 3.09; N, 8.58 found: C, 59.13; H, 3.26; N, 8.49. 1H NMR (600 MHz, CD2Cl2) δ: 8.04 (s, 1H, Ar), 7.75 (d, 1H, J = 8.1, Ar), 7.63 (d, 1H, J = 8.1, Ar), 7.54 (d, 1H, J = 8.1, Ar), 7.48 (t, 1H, J = 7.7, Ar), 7.35 (t, 1H, J = 7.3, Ar), 7.29 (t, 1H, J = 7.7, Ar), 7.09 (m, 2H, Ar), 6.50 (s, 1H, OH). 13C NMR (90 MHz, CD2Cl2) δ: 163.3, 156.0, 152.2, 151.1, 149.6, 137.1, 129.4, 128.3, 127.6, 124.4, 123.5, 121.0, 117.1, 115.7, 112.2, 110.5. IR, ν, cm−1: 3487, 3456, 3139, 3059, 2958, 2929, 2858, 1728, 1610, 1560, 1485, 1333, 1288, 1257, 1220, 1175, 1162, 1072, 1034, 883, 741, 668. m/z (%): 326 (M+, 76), 262 (100), 245 (36), 143 (98), 119 (63) 91 (19), 64 (17). HRMS m/z (ESI)327.0254 [M + H]+ (calc. for C16H10N2O2S2, m/z 327.0256).

3.3. General Procedure for the Thermolysis of 2-((4-aryl(hetaryl)-5H-1,2,3-dithiazol-5-ylidene)amino)phenols 7 in Various Solvents

Dithiazole 7 (0.2 mmol) was refluxed in solvent (10 mL) up to its disappearance (TLC control) for the time given below. The reaction mixture was evaporated, and the residue was separated by column chromatography (Silica gel Merck 60, light petroleum and then light petroleum–CH2Cl2, then CH2Cl2).
Benzo[d]oxazol-2-yl(phenyl)methanone (8a)
EtOH, 1.5 h, yield 44 mg (99%). Colorless solid, m.p. 72–73 °C. (m.p. 74–75 °C) [36]. The 1H and 13C NMR spectra were similar to those samples prepared by the literature method [45].
Benzo[d]oxazol-2-yl(4-fluorophenyl)methanone (8b)
EtOH, 1 h, yield 47 mg (97%). Colorless solid, m.p. 138–141 °C. (m.p. 108–110 °C) [36]. The 1H and 13C NMR spectra were similar to those described in the literature [45].
Benzo[d]oxazol-2-yl(4-methoxyphenyl)methanone (8c)
EtOH, 1 h, yield 50 mg (98%). Colorless solid, m.p. 123–124 °C. (m.p. 78–80 °C) [36]. The 1H and 13C NMR spectra were similar to those described in the literature [45].
Benzo[d]oxazol-2-yl(4-bromophenyl)methanone (8d)
EtOH, 1.5 h, yield 59 mg (98%). Light yellow solid, m.p. 113–115 °C. (m.p. 140–142 °C) [37]. The 1H and 13C NMR spectra were similar to those described in the literature [46].
Benzo[d]oxazol-2-yl(4-nitrophenyl)methanone (8e)
EtOH, 1.5 h, yield 49 mg (92%). Colorless solid, m.p. 160–161 °C. (m.p. 139–141 °C) [36]. The 1H and 13C NMR spectra were similar to those described in the literature [45].
Benzo[d]oxazol-2-yl(thiophen-2-yl)methanone (8f)
EtOH, 8 h, yield 40 mg (87%). Colorless solid, m.p. 119–120 °C. (m.p. 105–107 °C) [36]. The 1H and 13C NMR spectra were similar to those described in the literature [45].
Benzo[d]oxazol-2-yl(benzofuran-2-yl)methanone (8g)
EtOH, 5 h, yield 59 mg (89%). Colorless solid, m.p. 210–211 °C. Anal. calcd. for C16H9NO3: C, 73.00; H, 3.45; N, 5.32 found: C, 73.15; H, 3.56; N, 5.11. 1H NMR (600 MHz, CD2Cl2) δ: 8.75 (s, 1H, Ar), 8.02 (d, 1H, J = 7.9, Ar), 7.91 (d, 1H, J = 7.9, Ar), 7.80 (d, 1H, J = 7.9, Ar), 7.72 (d, 1H, J = 8.6, Ar), 7.65–7,58 (m, 2H, Ar), 7.56 (t, 1H, J = 7.6, Ar), 7.43 (t, 1H, J = 7.9, Ar). 13C NMR (150 MHz, CD2Cl2) δ: 169.0, 156.9, 156.8, 151.0, 150.7, 141.1, 129.9, 126.9, 127.6, 126.3, 124.6, 124.6, 122.6, 121.2, 112.8, 112.2. IR, ν, cm−1: 3440, 3139, 3105, 3065, 2960, 2926, 2855, 2361, 2342, 1657, 1613, 1542, 1528 1478, 1445, 1326, 1309, 1265, 1124, 1006, 991, 895, 737. m/z (EI) 263 (M+, 39), 145 (100), 118 (4), 89 (71), 28 (10). HRMS m/z (ESI)302.0215 [M + K]+ (calc. for C16H9KNO3, m/z 302.0214).
Benzo[d]oxazol-2-yl(phenyl)methanimine (9a)
MeOH, 1.5 h, yield 43 mg (98%). Colorless amorphous solid, m.p. 40–42 °C. Anal. calcd. for C14H10N2O: C, 73.00; H, 3.45; N, 5.32 found: C, 73.15; H, 3.56; N, 5.11. 1H NMR (500 MHz, CD3OD) δ: 8.07(s, 1H, Ar), 7.85 (d, 1H, J = 7.3, Ar), 7.76–7.72 (m, 2H, Ar), 7.59(d, 1H, J = 7.3, Ar), 7.55–7.52 (m, 3H, Ar), 7.48 (t, 1H, J = 7.6, Ar), 7.38 (d, 1H, J = 6.1, Ar). 13C NMR (150 MHz, CD3OD) δ: 162.4, 150.3, 140.6, 133.7, 130.8, 129.2, 128.8, 127.7, 126.9, 125.6, 124.9, 110.7. IR, ν, cm−1 3463, 3434, 2363, 2339, 1721, 1704, 1634, 1562, 1545, 1526, 1511, 1400, 1369, 1041, 1000, 966, 671, 571, 430. m/z (%): 222 (M+, 100), 119 (84), 104 (58), 91 (38), 77 (44). HRMS m/z (ESI)245.0688 [M + Na]+ (calcd. for C14H10NaN2O, m/z 245.0685).
Benzo[d]oxazol-2-yl(4-fluorophenyl)methanimine (9b)
MeOH, 1 h, yield 46 mg (99%). Colorless solid, m.p. 103–104 °C. Anal. calcd. for C14H9FN2O: C, 69.99; H, 3.78; N, 11.66 found: C, 70.23; H, 3.98; N, 11.82. 1H NMR (500 MHz, CD3OD) δ: 8.06 (s, 1H, Ar), 7.79 (d, 1H, J = 8.1, Ar), 7.69 (d, 1H, J = 8.1, Ar), 7.53–7.40 (m, 3H, Ar), 7.21 (t, 3H, J = 8.8, Ar). 13C NMR (125 MHz, CD2Cl2) δ: 169.9, 150.0, 139.9 (J = 173), 131.1, 131.0 (, 128.3, 127.0, 124.9, 124.1, 114.7, 114.5, 110.7. IR, ν, cm−1: 3435, 3270, 3045, 1602, 1507, 1451, 1414, 1381, 1334, 1230, 1188, 1158, 1104, 952, 843, 744, 633. m/z (%): 240 (M+,100), 122 (68), 119 (94), 95 (57), 75 (54). HRMS m/z (ESI)263.0587 [M + Na]+ (calcd. for C14H9NaFN2O, m/z 263.0591).
Benzo[d]oxazol-2-yl(4-methoxyphenyl)methanimine (9c)
MeOH, 1 h, yield 43 mg (87%). Colorless amorphous solid, m.p. 63–64 °C. Anal. calcd. for C15H12N2O2: C, 71.42; H, 4.79; N, 11.10 found: C, 71.55; H, 4.92; N, 4.52. 1H NMR (500 MHz, CD3OD) δ: 8.07 (s, 1H, Ar), 7.85(d, 1H, J = 7.9, Ar), 7.75 (d, 1H, J = 8.6, Ar), 7.55 (t, 1H, J = 7.3, Ar), 7.48(t, 1H, J = 7.3, Ar), 7.06 (d, 2H, J = 9.2, Ar) 3.89 (s, 3H, MeO). 13C NMR (125 MHz, CD3OD) δ: 162.4, 150.2, 140.5, 132.9, 130.4, 126.8, 124.9, 120.5, 119.1, 113.1, 112.8, 110.7, 54.2. IR, ν, cm−1 3465, 3433, 3402, 3276, 3084, 3014, 2951, 2931, 2913, 2838, 2382, 2346, 2290, 1777, 1737, 1721, 1704, 1686, 1653, 1608, 1539, 1454, 1421, 1377, 1337, 1306, 1256, 1175, 1154, 1110, 1070, 1029, 1004, 951, 913, 893, 832, 808, 745, 712, 651, 625, 610, 563, 507, 427. m/z (%) 252 (M+,100), 237 (6), 221 (13), 134 (75), 119 (37), 91 (11), 77 (7). HRMS m/z (ESI)275.0791 [M + Na]+ (calcd. for C15H12NaN2O2, m/z 275.0791).
Benzo[d]oxazol-2-yl(4-bromophenyl)methanimine (9d)
MeOH.1.2 h, yield 60 mg (98%). Colorless solid, m.p. 82–83 °C. Anal. calcd. for C14H9BrN2O: C, 55.84; H, 3.01; N, 9.30 found: C, 55.99; H, 3.23; N, 9.11. 1H NMR (600 MHz, CD3OD) δ: 8.07 (d, 1H, J = 6.6, Ar), 7.88 (d, 1H, J = 8.1, Ar), 7.78 (d, 1H, J = 8.1, Ar), 7.73 (d, 2H, J = 8.8, Ar), 7.58 (t, 1H, J = 8.4, Ar), 7.51 (t, 1H, J = 7.3, Ar). 13C NMR (150 MHz, CD2Cl2) δ: 151.4, 141.7, 133.0, 132.0, 129.3, 128.2, 126.3, 126.1, 125.3, 121.8, 111.8, 111.3. IR, ν, cm−1: 3587, 3492, 3435, 2926, 2856, 1591, 1530, 1485, 1459, 1357, 1237, 1191, 1148, 1072, 1010, 945, 862, 826, 773, 738, 691. m/z (%): 299 (M+, 32%), 221 (7), 182 (21), 119 (100), 91 (43), 76 (25). HRMS m/z (ESI)322.9792 [M + Na]+ 324.9770 [M + Na]+ (calcd. for C14H9NaBrN2O, m/z 322.9792, 324.9770).
Benzo[d]oxazol-2-yl(4-nitrophenyl)methanimine (9e)
MeOH, 1.5 h, yield 60 mg (97%). Colorless solid, m.p. 130–131 °C. Anal. calcd. for C14H9N3O3: C, 62.92; H, 3.39; N, 15.72 found: C, 63.13; H, 3.52; N, 15.48. 1H NMR (600 MHz, CD3OD) 8.10–7.94 (m, 4H, Ar), 7.80 (d, 1H, J = 9.5, Ar), 7.72 (d, 1H, J = 5.9, Ar), 7.42–7.26 (m, 2H, Ar). 13C NMR (150 MHz, CD2Cl2) δ: 169.5, 152.0, 148.1, 147.9, 132.4, 132.2, 127.7, 124.4, 121.1, 119.5, 118.6, 110.6. IR, ν, cm−1: 3467, 3436, 3267, 3109, 1589, 1521, 1482, 1447, 1408, 1347, 1238, 1156, 1106, 952, 917, 852, 743, 682. m/z (%): 267 (M+, 64%), 221 (3), 149 (7), 119 (100), 103 (28), 76 (25), 46 (9). HRMS m/z (ESI)290.0536 [M + Na]+ (calcd. for C14H9NaN3O3, m/z 290.0536).
Benzo[d]oxazol-2-yl(thiophen-2-yl)methanimine (9f)
MeOH, 1.5 h, yield 43 mg (96%). Colorless solid, m.p. 69–70 °C. Anal. calcd. for C12H8N2OS: C, 63.14; H, 3.53; N, 12.27 found: C, 63.07; H, 3.55; N, 12.30. 1H NMR (300 MHz, CD2Cl2) δ: 11.04 (s, 1H), 8.42 (d, 1H, J = 1.4, Ar), 7.92 (d, 1H, J = 7.5, Ar), 7.72 (d, 1H, J = 7.9, Ar), 7.63 (d, 1H, J = 4.8, Ar), 7.61–7.44 (m, 2H, Ar), 7.25 (t, 1H, J = 4.3, Ar). 13C NMR (75 MHz, CD2Cl2) δ: 156.9, 150.8, 141.5, 137.8, 133.1, 131.1, 128.3, 127.6, 125.7, 121.8, 112.1, 111.5. IR, ν, cm−1: 3464, 3296, 3088, 2926, 1638, 1571, 1541, 1431, 1229, 1137, 1048, 942, 836, 744, 730, 611. m/z (%): 228 (M+, 77%), 144 (23), 120 (6), 109 (100), 84 (7), 64 (6), 76 (5). HRMS m/z (ESI) 229.0432 [M + H]+ (calcd. for C12H9N2OS, m/z 229.0430).
Benzo[d]oxazol-2-yl(benzofuran-2-yl)methanimine (9g)
MeOH, 1.5 h, yield 50 mg (95%). Colorless solid, m.p. 159–161 °C. Anal. calcd. for C16H10N2O2: C, 73.27; H, 3.84; N, 10.68 found: C, 73.45; H, 3.90; N, 10.42. NMR (600 MHz, CD3OD) δ: 8.11 (s, 1H, NH), 7.83 (d, 1H, J = 8.1, Ar), 7.70 (d, 1H, J = 7.3, Ar), 7.65 (d, 1H, J = 8.1, Ar), 7.53 (d, 1H, J = 8.1, Ar), 7.44 (t, 1H, J = 7.7, Ar), 7.39 (t, 2H, J = 7.7, Ar), 7.26 (t, 1H, J = 7.3, Ar). 13C NMR (90 MHz, CD3OD) δ: 154.7, 152.7, 149.8, 140.4, 128.8, 127.8, 126.7, 126.5, 124.6, 123.0, 120.6, 120.1, 111.7, 111.1, 110.9, 110.7. IR, ν, cm−1: 3448, 3287, 3138, 3092, 3065, 2957, 2924, 2853, 1654, 1615, 1590, 1557, 1525, 1474, 1450, 1229, 1170, 1123, 1005, 974, 894, 873, 734. m/z (%): 262 (M+, 100), 245 (24), 143 (81), 119 (51), 94 (13), 89 (50), 63 (34). HRMS m/z (ESI)301.0376 [M + K]+ (calcd. for C16H10N2O2K, m/z 301.0374).
General procedure for the thermolysis of benzo[d]oxazol-2-yl(aryl(hetaryl))methanimines 9 in MeCN
Methanimine 9 (0.2 mmol) was refluxed in MeCN (10 mL) up to its disappearance (TLC control) for the time given below. Reaction mixture was evaporated and the residue was separated by column chromatography (Silica gel Merck 60, light petroleum and then light petroleum–CH2Cl2, then CH2Cl2).
2-((2-(Benzo[d]oxazol-2-yl)-2,5-diphenyl-2H-imidazol-4-yl)amino)phenol (10a)
Yield 26 mg (58%). Colorless solid, m.p. 246–248 °C. Anal. calcd. for C28H20N4O2: C, 75.66; H, 4.54; N, 12.60 found: C, 75.70; H, 4.52; N, 12.56. 1H NMR (300 MHz, DMSO-d6,) δ: 10.26 (s, 1H, NH), 8.54 (d, 1H, J = 5.7, Ar), 8.02–7.90 (m, 5H, Ar), 7.71 (m, 5H, Ar), 7.47–7.41 (m, 5H, Ar), 6.94 (s, 3H, Ar). 13C NMR (125 MHz, DMSO-d6,) δ: 164.8, 163.8, 156.3, 150.3, 146.2, 140.3, 138.4, 131.7, 130.0, 129.6, 128.5, 128.3, 128.2, 128.1, 127.5, 125.8, 124.8, 123.6, 120.2, 119.5, 118.7, 114.5, 111.1, 100.8. IR, ν, cm−1: 3390, 3083, 1636, 1611, 1581, 1529, 1458, 1243, 746, 696, 568. m/z (%): 444 (M+, 12), 414 (26), 310 (9), 222 (100), 207 (48), 120 (16), 93 (41), 77 (12). HRMS m/z (ESI)445.1648 [M + H]+ (calc. for C28H21N4O2, m/z 445.1659).
2-((2-(Benzo[d]oxazol-2-yl)-2,5-bis(4-fluorophenyl)-2H-imidazol-4-yl)amino)phenol (10b)
Yield 40 mg (83%). Colorless solid, m.p. 217–219 °C. Anal. calcd. for C28H18F2N4O2: C, 69.99; H, 3.78; N, 11.66 found: C, 69.90; H, 3.82; N, 11.73. 1H NMR (300 MHz, DMSO-d6,) δ: 10.25 (s, 1H, NH), 8.46 (d, 1H, J = 7.4, Ar), 8.05 (s, 1H, OH), 8.03 (s, 2H, Ar), 7.96–7.91 (m, 2H, Ar), 7.76 (d, 1H, J = 8.7, Ar), 7.10 (d, 1H, J = 8.6, Ar), 7.53 (t, 2H, J = 8.7, Ar), 7.40–7.38 (m, 2H, Ar), 7.29 (t, 2H, J = 8.8, Ar), 6.95 (s, 3H, Ar). 13C NMR (125 MHz, DMSO-d6,) δ: 155.6 (J = 192), 155.5, 153.4 (J = 246), 147.8, 141.6, 137.8, 131.6, 125.8, 122.4, 121.7, 121.6, 118.7, 117.1, 116.1, 115.1, 111.5, 110.8, 110.4, 107.9, 106.5, 106.3, 106.0, 102.4, 91.4. IR, ν, cm−1: 3423, 3068, 2926, 1632, 1589, 1572, 1529, 1506, 1456, 1236, 1157, 1081, 832, 747, 524. m/z (%): 480 (M+, 75%), 359 (100), 346 (96), 239 (23), 225 (13), 197 (10), 122 (15), 91 (6). HRMS m/z (ESI)481.1477 [M + H]+ (calc. for C28H19F2N4O2, m/z 481.1471).
2-((2-(Benzo[d]oxazol-2-yl)-2,5-bis(4-methoxyphenyl)-2H-imidazol-4-yl)amino)phenol (10c)
Yield 42 mg (84%). Colorless crystals, m.p. 242–244 °C. Anal. calcd. for C30H24N4O4: C, 71.42; H, 4.79; N, 11.10 found: C, 71.50; H, 4.65; N, 11.05. 1H NMR (500 MHz, DMSO-d6,) δ: 10.28 (s, 1H, NH), 8.53 (d, 1H, J = 7.4, Ar), 7.99 (s, 1H, OH), 7.91 (d, 2H, J = 8.7, Ar), 7.79 (d, 2H, J = 8.8, Ar), 7.74 (d, 1H, J = 7.2, Ar), 7.69 (d, 1H, J = 7.2, Ar), 7.42–7.34 (m, 2H, Ar), 7.23 (d, 2H, J = 8.7, Ar), 7.01 (d, 2H, J = 8.8, Ar), 6.97–6.90 (m, 3H, Ar), 3.90 (s, 3H, CH3), 3.79 (s, 3H, CH3). 13C NMR (125 MHz, DMSO-d6,) δ: 155.5, 155.2, 153.1, 150.6, 147.5, 141.5, 137.4, 131.6, 121.9, 121.3, 120.7, 118.9, 116.9, 116.0, 114.7, 113.5, 111.4, 110.8, 110.0, 106.3, 105.8, 104.9, 102.3, 91.4, 46.8, 46.5. IR, ν, cm−1: 3391, 2927, 2840, 1608, 1582, 1509, 1458, 1250, 1172, 1026, 831, 747. m/z (%): 504 (M+, 9), 472 (25), 356 (82), 328 (37), 252 (100), 120 (5), 106(8), 93 (7), 78(14). HRMS m/z (ESI)505.1887 [M + H]+ (calc. for C30H25N4O4 m/z 505.1870).
2-((2-(Benzo[d]oxazol-2-yl)-2,5-bis(4-bromophenyl)-2H-imidazol-4-yl)amino)phenol (10d)
Yield 40 mg (66%). Colorless crystals, m.p. 251–253 °C. Anal. calcd. for C28H18Br2N4O2: C, 55.84; H, 3.01; N, 9.30 found: C, 55.84; H, 3.10; N, 9.25. 1H NMR (300 MHz, CD2Cl2) δ: 10.25 (s, 1H, NH), 7.85 (d, 2H, J = 8.2, Ar), 7.81–7.67 (m, 6H, Ar), 7.64–7.53 (m, 4H, Ar), 7.42–7.35 (m, 2H, Ar), 7.07 (t, 1H, J = 6.3, Ar), 6.96 (t, 2H, J = 7.2, Ar). 13C NMR (75 MHz, CD2Cl2) δ: 163.9, 163.4, 157.6, 151.4, 147.9, 147.8, 140.8, 137.3, 133.0, 132.7, 132.2, 131.8, 130.3, 130.2, 129.0, 126.3, 126.0, 125.0, 121.3, 121.0, 120.6, 111.2, 100.4. IR, ν, cm−1: 3407, 2925, 2854, 1635, 1591, 1579, 1457, 1243, 1072, 1010, 821, 748. m/z (%): 604 (M+ + 2, 13%), 602 (M+, 14), 522 (18), 483 (100), 446 (90), 442 (5), 300 (23), 284 (45), 167 (17), 156 (14), 107 (35), 79 (37). HRMS m/z (ESI)600.9875 [M + H]+ (calc. for C28H19Br2N4O2 m/z 600.9869).
2-((2-(Benzo[d]oxazol-2-yl)-2,5-bis(4-nitrophenyl)-2H-imidazol-4-yl)amino)phenol (10e)
Yield 40 mg (62%). Light yellow crystals, m.p. 213–215 °C. Anal. calcd. for C28H18N6O6: C, 62.92; H, 3.39; N, 15.72; O, 17.96 found: C, 62.85; H, 3.30; N, 15.81. 1H NMR (300 MHz, CD2Cl2,) 8.69 (d, 1H, J = 6.6), 8.35 (d, 2H, J = 8.1, Ar), 8.42–8.14 (m, 4H, Ar), 8.00 (t, 1H, J = 7.7, Ar), 7.89 (d, 2H, J = 8.1, Ar), 7.65 (d, 1H, J = 7.3, Ar), 7.47 (d, 1H, J = 7.3, Ar), 7.34–7.29 (m, 3H, Ar), 6.89 (t, 2H, J = 6.6, Ar), 6.78 (d, 1H, J = 4.4, Ar). 13C NMR (75 MHz, CD2Cl2,) δ: 163.7, 162.5, 156.9, 151.1, 149.8, 146.7, 144.1, 135.5, 129.7, 129.7, 126.1, 125.5, 125.0, 124.6, 123.5, 121.8, 121.2, 120.9, 120.4, 120.3, 116.9, 116.2, 111.1, 100.7. IR, ν, cm−1: 3420, 2956, 2927, 2855, 1776, 1736, 1720, 1703, 1685, 1639, 1583, 1521, 1458, 1406, 1347, 1311, 1282, 1245, 1218, 1201, 1173, 1107, 1076, 1039, 1014, 984, 932, 888, 849, 747, 692. m/z (%): 534 (M+, 38%), 488 (100), 435 (26), 411 (45), 365 (28), 268 (7), 148 (19), 123 (18), 79 (5). HRMS m/z (ESI)535.1366 [M + H]+ (calc. for C28H19N6O6, m/z 535.1361).
2-((2-(Benzo[d]oxazol-2-yl)-2,5-bis(thiophen-2-yl)-2H-imidazol-4-yl)amino)phenol (10f)
Yield 22 mg (48%). Dark brown amorphous crystals, m.p. 142–144 °C. Anal. calcd. for C24H16N4O2S2: C, 63.14; H, 3.53; N, 12.27 found: C, C, 63.11; H, 3.54; N, 12.32. 1H NMR (300 MHz, DMSO-d6,) 10.39 (s, 1H, NH), 8.42 (d, 1H, J = 7.4, Ar), 8.28 (s, 1H, OH), 8.08 (m, 2H, Ar), 8.04 (d, 1H, J = 3.5, Ar), 7.79–7.71 (m, 2H, Ar), 7.59 (d, 1H, J = 5.1, Ar), 7.45–7.40 (m, 4H, Ar), 7.13 (t, 1H, J = 8.7, Ar), 6.98–6.94 (m, 3H, Ar). 13C NMR (75 MHz, DMSO-d6,) δ: 158.4, 156.2, 150.2, 146.6, 140.2, 139.4, 132.8, 131.7, 130.5, 130.1, 129.1, 127.5, 127.3, 126.9, 126.7, 125.9, 124.8, 123.9, 121.9, 120.2, 119.4, 119.3, 114.6, 111.1. IR, ν, cm−1: 3392, 3116, 2927, 2855, 2362, 1629, 1577, 1531, 1457, 1384, 1239, 1067, 836, 748, 710. m/z (%): 456 (M+, 5%), 347 (21), 322 (50), 284 (100), 228 (18), 119 (19), 110 (15), 91 (9). HRMS m/z (ESI)457.0797 [M + H]+ (calc. for C24H17N4O2S2, m/z 457.0787).
2-((2-(Benzo[d]oxazol-2-yl)-2,5-bis(benzofuran-2-yl)-2H-imidazol-4-yl)amino)phenol (10g)
Yield 30 mg (57%). Yellow crystals, m.p. 231–233 °C. Anal. calcd. for C32H20N4O4: C, 73.45; H, 3.99; N, 10.32 found: C, 73.27; H, 3.84; N, 10.68. 1H NMR (300 MHz, CD2Cl2) δ: 8.94 (s, 1H, NH), 7.95 (d, 1H, J = 6.6, Ar), 7.89 (s, 1H, Ar), 7.83 (d, 1H, J = 7.3, Ar), 7.76 (d, 1H, J = 8.1, Ar), 7.64 (d, 1H, J = 7.3, Ar), 7.59–7.29 (m, 8H, Ar), 7.08 (s, 1H, Ar), 6.94 (d, 2H, J = 8.7, Ar), 6.85 (s, 1H, Ar). 13C NMR (150 MHz, CD2Cl2) δ: 161.9, 158.6, 155.8, 155.7, 152.0, 151.4, 147.7, 147.6, 140.8, 128.1, 127.9, 127.4, 127.3, 126.3, 125.9, 125.3, 125.2, 124.8, 123.5, 123.1, 121.9, 121.5, 120.9, 120.7, 120.0, 118.4, 116.8, 113.4, 112.2, 111.8, 111.4, 106.3. IR, ν, cm−1: 3386, 3115, 3064, 2923, 2853, 1632, 1592, 1557, 1506, 1455, 1348, 1281, 1248, 1166, 1147, 1106, 1068, 1002, 930, 874, 822, 746, 618, 430. m/z (%): 524 (M+, 16%), 262 (51), 145 (96), 119 (41), 94 (100), 63 (80). HRMS m/z (ESI)563.1116 [M + K]+ (calcd. for C32H20N4O4, m/z 563.1116).

4. Conclusions

In summary, a new unprecedented formation of four substituted imidazoles containing a benzoxazole ring from the thermolysis of readily available 2-((4-aryl(hetaryl)-5H-1,2,3-dithiazol-5-ylidene)amino)phenols was developed. The possibility of the imidazole ring formation from the compounds containing two methanimino groups was proved. Finally, 4-aryl(hetaryl)-substituted 5H-1,2,3-dithiazoles gave, upon thermolysis, different products from 4-chloro derivatives where the chlorine atom was readily expelled as a chloride anion, and the cyano group was generated. 2,2-Diaryl-2H-imidazol-4-amines are of interest as a BACE-1 inhibitors for the treatment of Alzheimer’s disease or dementia [47,48].

Supplementary Materials

The Supplementary Materials are available online. Characterization data including 1H and 13C NMR spectra for novel compounds and single crystal X-ray crystallography data (CCDC 1850211 and 1850212 for compounds 9f and 10b, respectively).

Author Contributions

O.A.R. conceived and designed the study; L.S.K., I.V.B., M.A.T., and V.V.P. performed the experiments; L.S.K. analyzed the data; K.A.L. carried out the XRD studies and DFT calculations. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by The Scientific Schools Development Program by the Zelinsky Institute of Organic Chemistry, grant number NSh 31.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Konstantinova, L.S.; Rakitin, O.A. Synthesis and properties of 1,2,3-dithiazoles. Russ. Chem. Rev. 2008, 77, 521–546. [Google Scholar] [CrossRef]
  2. Rakitin, O. 1,2-Oxa/thia-3-azoles. In Comprehensive Heterocyclic Chemistry III; Katritzky, A.R., Ramsden, C.A., Scriven, E.F.V., Taylor, R.J.K., Eds.; Elsevier BV: Amsterdam, The Netherlands, 2008; Volume 6, pp. 1–36. [Google Scholar]
  3. Rakitin, O.A.; Zibarev, A.V. Synthesis and Applications of 5-Membered Chalcogen-Nitrogen π-Heterocycles with Three Heteroatoms. Asian J. Org. Chem. 2018, 7, 2397–2416. [Google Scholar] [CrossRef]
  4. Besson, T.; Rees, C.W.; Cottenceau, G.; Pons, A.-M. Antimicrobial evaluation of 3,1-benzoxazin-4-ones, 3,1-benzothiazin-4-ones, 4-alkoxyquinazolin-2-carbonitriles and N-arylimino-1,2,3-dithiazoles. Bioorg. Med. Chem. Lett. 1996, 6, 2343–2348. [Google Scholar] [CrossRef]
  5. Oppedisano, F.; Catto, M.; Koutentis, P.A.; Nicolotti, O.; Pochini, L.; Koyioni, M.; Introcaso, A.; Michaelidou, S.S.; Carotti, A.; Indiveri, C. Inactivation of the glutamine/amino acid transporter ASCT2 by 1,2,3-dithiazoles: Proteoliposomes as a tool to gain insights in the molecular mechanism of action and of antitumor activity. Toxicol. Appl. Pharmacol. 2012, 265, 93–102. [Google Scholar] [CrossRef] [PubMed]
  6. Charalambous, A.; Koyioni, M.; Antoniades, I.; Pegeioti, D.; Eleftheriou, I.; Michaelidou, S.S.; Amelichev, S.A.; Konstantinova, L.S.; Rakitin, O.A.; Koutentis, P.A.; et al. 1,2,3-Dithiazoles–new reversible melanin synthesis inhibitors: A chemical genomics study. MedChemComm 2015, 6, 935–946. [Google Scholar] [CrossRef]
  7. Asquith, C.R.M.; Konstantinova, L.S.; Laitinen, T.; Meli, M.L.; Poso, A.; Rakitin, O.A.; Hofmann-Lehmann, R.; Hilton, S.T. Evaluation of Substituted 1,2,3-Dithiazoles as Inhibitors of the Feline Immunodeficiency Virus (FIV) Nucleocapsid Protein via a Proposed Zinc Ejection Mechanism. ChemMedChem 2016, 11, 2119–2126. [Google Scholar] [CrossRef]
  8. Asquith, C.R.M.; Meili, T.; Rakitin, O.A.; Baranovsky, I.V.; Konstantinova, L.S.; Poso, A.; Rakitin, O.A.; Hofmann-Lehmann, R. Synthesis and comparison of substituted 1,2,3-dithiazole and 1,2,3-thiaselenazole as inhibitors of the feline immunodeficiency virus (FIV) nucleocapsid protein as a model for HIV infection. Bioorganic Med. Chem. Lett. 2019, 29, 1765–1768. [Google Scholar] [CrossRef]
  9. Beer, L.; Cordes, A.W.; Haddon, R.C.; Itkis, M.E.; Oakley, R.T.; Reed, R.W.; Robertson, C.M. A π-stacked 1,2,3-dithiazolyl radical. Preparation and solid state characterization of (Cl2C3NS)(ClC2NS2). Chem. Commun. 2002, 1872–1873. [Google Scholar] [CrossRef]
  10. Rakitin, O.A. Stable heterocyclic radicals. Russ. Chem. Rev. 2011, 80, 647–659. [Google Scholar] [CrossRef]
  11. Lekin, K.; Phan, H.; Winter, S.M.; Wong, J.W.L.; Leitch, A.A.; Laniel, D.; Yong, W.; Secco, R.A.; Tse, J.S.; Desgreniers, S.; et al. Heat, Pressure and Light-Induced Interconversion of Bisdithiazolyl Radicals and Dimers. J. Am. Chem. Soc. 2014, 136, 8050–8062. [Google Scholar] [CrossRef]
  12. Yu, X.; Mailman, A.; Lekin, K.; Assoud, A.; Robertson, C.M.; Noll, B.; Campana, C.F.; Howard, J.A.K.; Dube, P.A.; Oakley, R.T. Semiquinone-Bridged Bisdithiazolyl Radicals as Neutral Radical Conductors. J. Am. Chem. Soc. 2012, 134, 2264–2275. [Google Scholar] [CrossRef] [PubMed]
  13. Konstantinova, L.S.; Baranovsky, I.V.; Irtegova, I.G.; Bagryanskaya, I.Y.; Shundrin, L.A.; Zibarev, A.V.; Rakitin, O.A. Fused 1,2,3-Dithiazoles: Convenient Synthesis, Structural Characterization, and Electrochemical Properties. Molecules 2016, 21, 596. [Google Scholar] [CrossRef] [PubMed]
  14. Barclay, T.M.; Beer, L.; Cordes, A.W.; Haddon, R.C.; Itkis, M.I.; Oakley, R.T.; Preuss, K.E.; Reed, R.W. Trans-4,4′-Dichloro-1,1′,2,2′,3,3′-tetrathiadiazafulvalene (DC-TAF) and Its 1:1 Radical Cation Salts [DC-TAF][X]: Preparation and Solid-State Properties of BF4-, ClO4-, and FSO3-Derivatives. J. Am. Chem. Soc. 1999, 121, 6657–6663. [Google Scholar] [CrossRef]
  15. Appel, R.; Janssen, H.; Siray, M.; Knoch, F. Synthese und Reaktionen des 4,5-Dichlor-1,2,3-dithiazolium-chlorids. Eur. J. Inorg. Chem. 1985, 118, 1632–1643. [Google Scholar] [CrossRef]
  16. Kim, K. Synthesis and Reactions of 1,2,3-Dithiazoles. Sulfur Rep. 1998, 21, 147–207. [Google Scholar] [CrossRef]
  17. Koyioni, M.; Manoli, M.; Koutentis, P.A. The Reaction of DABCO with 4-Chloro-5H-1,2,3-dithiazoles: Synthesis and Chemistry of 4-[N-(2-Chloroethyl)piperazin-1-yl]-5H-1,2,3-dithiazoles. J. Org. Chem. 2015, 81, 615–631. [Google Scholar] [CrossRef]
  18. Kalogirou, A.S.; Michaelidou, S.S.; Koyioni, M.; Koutentis, P.A. Ring transformations of 2-hydroxy-(4-chloro-5H-1,2,3-dithiazol-5-ylideneamino)arenes. Tetrahedron 2015, 71, 7181–7190. [Google Scholar] [CrossRef]
  19. Kalogirou, A.S.; Michaelidou, S.S.; White, A.J.; Koutentis, P.A. Transformation of 2-(4-chloro-5H-1,2,3-dithiazol-5-ylideneamino)-6-ethoxy-4-phenylpyridine-3,5-dicarbonitrile into 4-aminopyrido[2,3-d]pyrimidines and 2-(pyrid-2-yl)guanidines. Tetrahedron 2015, 71, 1799–1807. [Google Scholar] [CrossRef]
  20. Koyioni, M.; Manoli, M.; Manolis, M.J.; Koutentis, P.A. Reinvestigating the Reaction of 1H-Pyrazol-5-amines with 4,5-Dichloro-1,2,3-dithiazolium Chloride: A Route to Pyrazolo[3,4-c]isothiazoles and Pyrazolo[3,4-d]thiazoles. J. Org. Chem. 2014, 79, 4025–4037. [Google Scholar] [CrossRef]
  21. Konstantinova, L.S.; Rakitin, O.A.; Rees, C.W.; Torroba, T.; White, A.J.P.; Williams, D.J. 1,2,4-Thiadiazole 4-oxides. J. Chem. Soc. Perkin Trans. 1999, 1, 2243–2248. [Google Scholar] [CrossRef]
  22. Clarke, D.; Emayan, K.; Rees, C.W. New synthesis of isothiazoles from primary enamines. J. Chem. Soc. Perkin Trans. 1 1998, 77–82. [Google Scholar] [CrossRef]
  23. Lee, H.; Kim, K. A facile synthesis of 2-cyano-4H-3,1-benzothiazines and 2-cyano-4H-3,1-benzoxazines. Heteroat. Chem. 1993, 4, 263–270. [Google Scholar] [CrossRef]
  24. Konstantinova, L.S.; Rakitin, O.A.; Rees, C.W.; Sivadasan, S.; Torroba, T. New route to 2-cyanobenzimidazoles. Tetrahedron 1998, 54, 9639–9650. [Google Scholar] [CrossRef]
  25. Lee, H.-S.; Chang, Y.-G.; Kim, K. A facile synthesis of 3-substituted 2-cyanoquinazolin-4(3H)-ones and 3-alkyl-2-cyanothieno[3,2-d]pyrimidin-4(3H)-onesvia1,2,3-dithiazoles. J. Heterocycl. Chem. 1998, 35, 659–668. [Google Scholar] [CrossRef]
  26. English, R.F.; Rakitin, O.A.; Rees, C.W.; Vlasova, O.G. Conversion of imino-1,2,3-dithiazoles into 2-cyanobenzothiazoles, cyanoimidoyl chlorides and diatomic sulfur. J. Chem. Soc. Perkin Trans. 1997, 1, 201–206. [Google Scholar] [CrossRef]
  27. Koutentis, P.A.; Rees, C.W. Reactions of tetracyanoethylene oxide with 1,2,3-dithiazoles. J. Chem. Soc. Perkin Trans. 1998, 1, 2505–2510. [Google Scholar] [CrossRef]
  28. Emayan, K.; Rees, C.W. The reaction of acetophenone oximes with disulfur dichloride; 4-aryl-5-arylimino-1,2,3-dithiazoles and pentathiepino[6,7-c]pyrrole. Bull. Soc. Chim. Belg. 1997, 106, 605–611. [Google Scholar] [CrossRef]
  29. Koutentis, P.A.; Koyioni, M.; Michaelidou, S.S. The conversion of [(4-chloro-5H-1,2,3-dithiazol-5-ylidene)amino]azines into azine fused thiazole-2-carbonitriles. Org. Biomol. Chem. 2013, 11, 621–629. [Google Scholar] [CrossRef]
  30. Koyioni, M.; Manoli, M.; Koutentis, P.A. Synthesis of Fused 1,2,4-Dithiazines and 1,2,3,5-Trithiazepines. J. Org. Chem. 2014, 79, 9717–9727. [Google Scholar] [CrossRef]
  31. Konstantinova, L.S.; Bol’shakov, O.I.; Obruchnikova, N.V.; Laborie, H.; Tanga, A.; Sopena, V.; Lanneluc, I.; Picot, L.; Sable, S.; Thiéry, V.; et al. One-pot synthesis of 5-phenylimino, 5-thieno or 5-oxo-1,2,3-dithiazoles and evaluation of their antimicrobial and antitumor activity. Bioorg. Med. Chem. Lett. 2009, 19, 136–141. [Google Scholar] [CrossRef]
  32. Matta, C.F.; Boyd, R.J. The Quantum Theory of Atoms in Molecules: From Solid State to DNA and Drug Design; Wiley-VCH Verlag GmbH & Co. KgaA: Weinheim, Germany, 2007. [Google Scholar] [CrossRef]
  33. Espinosa, E.; Molins, E.; LeComte, C. Hydrogen bond strengths revealed by topological analyses of experimentally observed electron densities. Chem. Phys. Lett. 1998, 285, 170–173. [Google Scholar] [CrossRef]
  34. Wang, X.; Xu, D.; Miao, C.; Zhang, Q.; Sun, W. N-Bromosuccinimide as an oxidant for the transition-metal-free synthesis of 2-aminobenzoxazoles from benzoxazoles and secondary amines. Org. Biomol. Chem. 2014, 12, 3108–3113. [Google Scholar] [CrossRef] [PubMed]
  35. Wertz, S.; Kodama, S.; Studer, A. Amination of Benzoxazoles and 1,3,4-Oxadiazoles Using 2,2,6,6-Tetramethylpiperidine-N-oxoammonium Tetrafluoroborate as an Organic Oxidant. Angew. Chem. Int. Ed. 2011, 50, 11511–11515. [Google Scholar] [CrossRef] [PubMed]
  36. Wagh, Y.S.; Tiwari, N.J.; Bhanage, B.M. Metal-free synthesis of 2-aminobenzoxazoles using hypervalent iodine reagent. Tetrahedron Lett. 2013, 54, 1290–1293. [Google Scholar] [CrossRef]
  37. Cook, S.; Jefferies, L.; Weber, S. Iron-Catalyzed C–N Bond Formation via the Beckmann Rearrangement. Synlett 2014, 26, 331–334. [Google Scholar] [CrossRef]
  38. Sheldrick, G.M. A short history of SHELX. Acta Crystallogr. Sect. A Found. Crystallogr. 2007, 64, 112–122. [Google Scholar] [CrossRef]
  39. Sheldrick, G.M. Crystal structure refinement with SHELXL. Acta Crystallogr. Sect. C Struct. Chem. 2015, 71, 3–8. [Google Scholar] [CrossRef]
  40. Frisch, M.J.; Trucks, G.W.; Schlegel, H.B.; Scuseria, G.E.; Robb, M.A.; Cheeseman, J.R.; Scalmani, G.; Barone, V.; Petersson, G.A.; Nakatsuji, H.; et al. Gaussian 09, Revision D.01; Gaussian, Inc.: Wallingford, CT, USA, 2016. [Google Scholar]
  41. Perdew, J.P.; Ernzerhof, M.; Burke, K. Rationale for mixing exact exchange with density functional approximations. J. Chem. Phys. 1996, 105, 9982–9985. [Google Scholar] [CrossRef]
  42. Medvedev, M.G.; Bushmarinov, I.S.; Sun, J.; Perdew, J.P.; Lyssenko, K.A. Density functional theory is straying from the path toward the exact functional. Science 2017, 355, 49–52. [Google Scholar] [CrossRef]
  43. Grimme, S.; Antony, J.; Ehrlich, S.; Krieg, H. A consistent and accurate ab initio parametrization of density functional dispersion correction (DFT-D) for the 94 elements H-Pu. J. Chem. Phys. 2010, 132, 154104. [Google Scholar] [CrossRef]
  44. Grimme, S.; Ehrlich, S.; Goerigk, L. Effect of the damping function in dispersion corrected density functional theory. J. Comput. Chem. 2011, 32, 1456–1465. [Google Scholar] [CrossRef] [PubMed]
  45. Boominathan, S.S.K.; Hu, W.-P.; Senadi, G.C.; Vandavasi, J.K.; Wang, J.-J. A one-pot hypoiodite catalysed oxidative cycloetherification approach to benzoxazoles. Chem. Commun. 2014, 50, 6726–6728. [Google Scholar] [CrossRef] [PubMed]
  46. Fan, X.; He, Y.; Zhang, X.; Guo, S.; Wang, Y. Synthesis of heteroaryl ketones via tandem reaction of 1,1-dibromoethenes. Tetrahedron 2011, 67, 6369–6374. [Google Scholar] [CrossRef]
  47. Gravenfors, Y.; Viklund, J.; Blid, J.; Ginman, T.; Karlström, S.; Kihlström, J.; Kolmodin, K.; Lindström, J.; Von Berg, S.; Von Kieseritzky, F.; et al. New Aminoimidazoles as β-Secretase (BACE-1) Inhibitors Showing Amyloid-β (Aβ) Lowering in Brain. J. Med. Chem. 2012, 55, 9297–9311. [Google Scholar] [CrossRef]
  48. Blid, J.; Ginman, T.; Gravenfors, Y.; Karlström, S.; Kolmodin, K.; Lindstroem, J.; Plobeck, N.; Rahm, F.; Swahn, B.-M.; Viklund, J.; et al. Preparation of phenylimidazolamine derivatives for use in treatment of neurodegenerative diseases. Patent: 2011, WO2011/2407. Chem. Abstr. 2011, 154, 109611. [Google Scholar]
Sample Availability: Samples of the compounds are available from the authors.
Molecules 25 03768 sch001
Scheme 1. Synthesis of 5-arylimino-1,2,3-dithiazoles 2 and 4 and subsequent formation of benzo[d]oxazole derivatives 3 and 5.
Scheme 1. Synthesis of 5-arylimino-1,2,3-dithiazoles 2 and 4 and subsequent formation of benzo[d]oxazole derivatives 3 and 5.
Molecules 25 03768 sch001
Molecules 25 03768 sch002
Scheme 2. Synthesis of 2-((4-aryl(thien-2-yl)-5H-1,2,3-dithiazol-5-ylidene)amino)phenols 7.
Scheme 2. Synthesis of 2-((4-aryl(thien-2-yl)-5H-1,2,3-dithiazol-5-ylidene)amino)phenols 7.
Molecules 25 03768 sch002
Molecules 25 03768 sch003
Scheme 3. Thermolysis of 2-((4-aryl(thien-2-yl)-5H-1,2,3-dithiazol-5-ylidene)amino)phenols 7 in ethanol and methanol.
Scheme 3. Thermolysis of 2-((4-aryl(thien-2-yl)-5H-1,2,3-dithiazol-5-ylidene)amino)phenols 7 in ethanol and methanol.
Molecules 25 03768 sch003
Molecules 25 03768 g001
Figure 1. The general view of benzo[d]oxazol-2-yl(thien-2-yl)methanimine 9f in representation of atoms by thermal ellipsoids (p = 50%).
Figure 1. The general view of benzo[d]oxazol-2-yl(thien-2-yl)methanimine 9f in representation of atoms by thermal ellipsoids (p = 50%).
Molecules 25 03768 g001
Molecules 25 03768 g002aMolecules 25 03768 g002b
Figure 2. The molecular graphs of two isomers with trans- (A) and cis- (B) disposition of C=N bonds. The critical points (3, −1) and (3, +1) are shown by small green and red balls. The bond path for C-H···O and C-H···N interactions are shown by dashed lines.
Figure 2. The molecular graphs of two isomers with trans- (A) and cis- (B) disposition of C=N bonds. The critical points (3, −1) and (3, +1) are shown by small green and red balls. The bond path for C-H···O and C-H···N interactions are shown by dashed lines.
Molecules 25 03768 g002aMolecules 25 03768 g002b
Molecules 25 03768 sch004
Scheme 4. Synthesis of imidazoles 10 from methanimines 9.
Scheme 4. Synthesis of imidazoles 10 from methanimines 9.
Molecules 25 03768 sch004
Molecules 25 03768 g003
Figure 3. The general view of 2-((2-(benzo[d]oxazol-2-yl)-2,5-bis(4-fluorophenyl)-2H-imidazol-4-yl)amino)phenol 10b in representation of atoms by thermal ellipsoids (p = 50%).
Figure 3. The general view of 2-((2-(benzo[d]oxazol-2-yl)-2,5-bis(4-fluorophenyl)-2H-imidazol-4-yl)amino)phenol 10b in representation of atoms by thermal ellipsoids (p = 50%).
Molecules 25 03768 g003
Molecules 25 03768 g004
Figure 4. The molecular graph of 10b according to PBE1PBE/def-2-TZVP calculation. The critical points (3, −1) and (3, +1) are shown by small green and red balls. The bond path for C-H···H-N and C-H···N interactions is shown by dashed lines.
Figure 4. The molecular graph of 10b according to PBE1PBE/def-2-TZVP calculation. The critical points (3, −1) and (3, +1) are shown by small green and red balls. The bond path for C-H···H-N and C-H···N interactions is shown by dashed lines.
Molecules 25 03768 g004
Molecules 25 03768 g005
Figure 5. O-H···N and stacking bonded centrosymmetric dimer in the crystal of 10b.
Figure 5. O-H···N and stacking bonded centrosymmetric dimer in the crystal of 10b.
Molecules 25 03768 g005
Molecules 25 03768 sch005
Scheme 5. A suggested reaction path for the formation of imidazoles 9 from methanimines 8.
Scheme 5. A suggested reaction path for the formation of imidazoles 9 from methanimines 8.
Molecules 25 03768 sch005
Table 1. X-ray crystallographic data and refinement details for studied molecules.
Table 1. X-ray crystallographic data and refinement details for studied molecules.
9f10b
CCDC number19930401993041
Empirical formulaC28H18F2N4O2C12H8N2OS
Formula weight480.46228.26
T, K120120
Crystal systemMonoclinicMonoclinic
Space groupP21/nP21/n
Z (Z’)4 (1)4(1)
a, Å12.3650(12)6.1355(5)
b, Å12.9901(13)7.5454(6)
c, Å14.3314(14)22.0813(19)
α, °9090
β, °107.871(2)94.779(2)
γ, °9090
V, Å32190.9(4)1018.70(15)
Dcalc,gcm−31.4571.488
μ, cm−11.062.93
F(000)992472
2θmax, °5858
Reflections collected2515311900
Reflections unique (Rint)5821 (0.0410)2710 (0.0357)
Reflections with I > 2σ(I)45582443
Variables/restraints333149
R10.04250.0357
wR20.10920.0962
GOF1.0241.036
Largest difference in peak/hole (e/Å3)0.328/−0.2420.415/−0.342

Share and Cite

MDPI and ACS Style

Baranovsky, I.V.; Konstantinova, L.S.; Tolmachev, M.A.; Popov, V.V.; A. Lyssenko, K.; Rakitin, O.A. Synthesis of 2-((2-(Benzo[d]oxazol-2-yl)-2H-imidazol-4-yl)amino)-phenols from 2-((5H-1,2,3-Dithiazol-5-ylidene)amino)phenols through Unprecedented Formation of Imidazole Ring from Two Methanimino Groups. Molecules 2020, 25, 3768. https://doi.org/10.3390/molecules25173768

AMA Style

Baranovsky IV, Konstantinova LS, Tolmachev MA, Popov VV, A. Lyssenko K, Rakitin OA. Synthesis of 2-((2-(Benzo[d]oxazol-2-yl)-2H-imidazol-4-yl)amino)-phenols from 2-((5H-1,2,3-Dithiazol-5-ylidene)amino)phenols through Unprecedented Formation of Imidazole Ring from Two Methanimino Groups. Molecules. 2020; 25(17):3768. https://doi.org/10.3390/molecules25173768

Chicago/Turabian Style

Baranovsky, Ilia V., Lidia S. Konstantinova, Mikhail A. Tolmachev, Vadim V. Popov, Konstantin A. Lyssenko, and Oleg A. Rakitin. 2020. "Synthesis of 2-((2-(Benzo[d]oxazol-2-yl)-2H-imidazol-4-yl)amino)-phenols from 2-((5H-1,2,3-Dithiazol-5-ylidene)amino)phenols through Unprecedented Formation of Imidazole Ring from Two Methanimino Groups" Molecules 25, no. 17: 3768. https://doi.org/10.3390/molecules25173768

APA Style

Baranovsky, I. V., Konstantinova, L. S., Tolmachev, M. A., Popov, V. V., A. Lyssenko, K., & Rakitin, O. A. (2020). Synthesis of 2-((2-(Benzo[d]oxazol-2-yl)-2H-imidazol-4-yl)amino)-phenols from 2-((5H-1,2,3-Dithiazol-5-ylidene)amino)phenols through Unprecedented Formation of Imidazole Ring from Two Methanimino Groups. Molecules, 25(17), 3768. https://doi.org/10.3390/molecules25173768

Article Metrics

Back to TopTop